TESARO Inc., a Waltham, Mass.-based biotech licensing and developing cancer therapies and oncology supportive care products, has filed for an initial public offering of stock with the aim of raising $86.2 million. The firm last June raised $101 million in a Series B round led by West Coast venture firm Kleiner Perkins Caulfield & Byers, and other backers include New Enterprise Associates, which took part in a $20 million Series A that launched the firm in 2010. TESARO is seeking to trade on the Nasdaq under the symbol “TSRO.” Underwriters include Citigroup, Morgan Stanley and Leerink Swan.
